Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03352466 · ClinicalTrials.gov registry record · Phase 1
NasoShield Study of Safety and Immunogenicity
A Phase 1 study, sponsored by Altimmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 145
- Enrollment target
NCT03352466 is a Phase 1 study that has completed, run by Altimmune. The registered enrollment target is 145 participants.
The verdict
NCT03352466, a Phase 1 study, has completed, sponsored by Altimmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 145 participants
- Enrollment target
Study Summary
This study is a Phase 1, randomized, double-blind, placebo-controlled, dose-escalation clinical trial to evaluate the safety and immunogenicity of NasoShield in healthy adults 18 to 49 years of age.
Interventions
- OTHER Placebo
- BIOLOGICAL BioThrax
- BIOLOGICAL NasoShield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2018-01-18 |
| Est. Completion | 2019-05-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03352466
The ClinicalTrials.gov registry entry for NCT03352466 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Altimmune, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03352466 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03352466 about?
NCT03352466 is a clinical study titled "NasoShield Study of Safety and Immunogenicity". This study is a Phase 1, randomized, double-blind, placebo-controlled, dose-escalation clinical trial to evaluate the safety and immunogenicity of NasoShield in healthy adults 18 to 49 years of age.
What is the current status of trial NCT03352466?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 145 participants. The study started on 2018-01-18. Estimated completion is 2019-05-13.
What interventions are being tested in trial NCT03352466?
The interventions under investigation include: Placebo (OTHER), BioThrax (BIOLOGICAL), NasoShield (BIOLOGICAL).
Who is sponsoring clinical trial NCT03352466?
This trial is sponsored by Altimmune, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.